ROCKET PHARMACEUTICALS INC (RCKT)
US77313F1066 - Common Stock
Rocket Pharmaceuticals is Now Oversold (RCKT)
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
RCKT stock results show that Rocket Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rocket Pharmaceuticals (NASDAQ:RCKT) just reported results for the second quart...
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
RCKT Crosses Above Key Moving Average Level
Interesting RCKT Put And Call Options For September 20th
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is trading down after the company announced a regulatory update for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I). The FDA has issued a Complete Response Letter (CRL) to Rocket’s Biologics License Application for Kresladi, in which the FDA requested limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review. Ro
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals Enters Oversold Territory (RCKT)
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rocket Pharmaceuticals (NASDAQ:RCKT) just reported results for the first quarte...
RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024
RCKT stock results show that Rocket Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Oversold Conditions For Rocket Pharmaceuticals (RCKT)
First Week of June 21st Options Trading For Rocket Pharmaceuticals (RCKT)
RCKT Crosses Below Key Moving Average Level
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
FDA extends review period for Rocket gene therapy to June 30 (NASDAQ:RCKT)
Rocket Pharmaceuticals (RCKT) said the FDA has extended the priority review period for its gene therapy product Kresladi for the treatment of severe Leukocyte A
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
First Week of March 15th Options Trading For Rocket Pharmaceuticals (RCKT)
First Week of RCKT February 16th Options Trading
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Interesting RCKT Put And Call Options For July 2024
